Soleno Therapeutics (NASDAQ:SLNO) Cut to “Hold” at Wall Street Zen

Soleno Therapeutics (NASDAQ:SLNO) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Sunday.

Other equities analysts also recently issued research reports about the stock. HC Wainwright reduced their price objective on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Wednesday, March 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Thursday, January 22nd. Wolfe Research set a $60.00 price target on Soleno Therapeutics in a research note on Monday, January 12th. Oppenheimer decreased their price objective on Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Robert W. Baird set a $107.00 price objective on Soleno Therapeutics in a research report on Tuesday, January 13th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $104.54.

Soleno Therapeutics Trading Down 1.2%

Shares of SLNO stock opened at $33.22 on Friday. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of 144.44 and a beta of -3.16. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11. The firm has a 50-day moving average price of $39.58 and a 200 day moving average price of $49.85. Soleno Therapeutics has a twelve month low of $32.15 and a twelve month high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.16. The firm had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. Research analysts forecast that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Institutional Trading of Soleno Therapeutics

Institutional investors have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new stake in shares of Soleno Therapeutics during the 2nd quarter worth $25,000. Danske Bank A S purchased a new position in shares of Soleno Therapeutics in the 3rd quarter worth $27,000. Aster Capital Management DIFC Ltd acquired a new position in Soleno Therapeutics in the third quarter valued at $37,000. Global Retirement Partners LLC boosted its holdings in Soleno Therapeutics by 519.0% in the fourth quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock valued at $29,000 after acquiring an additional 519 shares during the last quarter. Finally, Quarry LP purchased a new stake in Soleno Therapeutics during the third quarter valued at about $47,000. 97.42% of the stock is owned by hedge funds and other institutional investors.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Neutral Sentiment: Multiple law firms and claim services are issuing investor alerts reminding shareholders of the May 5, 2026 lead‑plaintiff deadline and encouraging affected investors to come forward. These notices increase visibility of the litigation but are procedural in nature. SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026
• Negative Sentiment: Several firms (Hagens Berman, Kessler Topaz, Pomerantz, Rosen, etc.) have confirmed or publicized securities‑fraud class actions alleging material misstatements/omissions about Soleno’s Phase 3 program and the November 2025 disclosures about DCCR/VYKAT XR launch disruptions. This raises the risk of costly litigation, management distraction, and potential settlements. Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions — Hagens Berman
• Negative Sentiment: An analyst update from Oppenheimer (reported in media coverage) lowered expectations for the VYKAT XR launch and 2026 sales, trimming the growth/valuation story for Soleno and increasing downside risk if launch execution and uptake remain weak. A Look At Soleno Therapeutics (SLNO) Valuation As Oppenheimer Updates Vykat XR Launch And 2026 Sales Outlook

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.